Brez internetne povezave — prikazana je shranjena različica strani.

Biogen Inc

USUSD
← Na filter delnic

Biogen Inc (US:BIIB) — Biotechnology: Biological Products (No Diagnostic Substances). Število borz, na katerih se trgujejo delnice družbe: 3. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O podjetju

Spletna stran
biogen.com
Odnosi z vlagatelji
investors.biogen.com/
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sedež
Cambridge, United States
Izvršni direktor
Michel Vounatsos
Zaposleni
7 500
Ustanovljena
1978
Delnice v obtoku
147.75 mio. na dan 2026-07-27
Prosto prenosljive delnice
147.22 mio.
Tržna kapitalizacija
33.79 mrd. USD
Notranje osebe
0.19%
Institucionalni vlagatelji
99.5%
Panoga (SIC)
Biological Products, (No Diagnostic Substances)
Pravna oblika
XTIQ
ISIN
US09062X1037
LEI
W8J5WZB5IY3K0NDQT671
Delež izplačila
0%
FCF
2.42 mrd. USD
Dolg
6.29 mrd. USD
2.6 let FCF
Dividendni staž
—
Dobički, FCF in izplačane dividende — za 12 mesecev do 31.03.2026 (najnovejše poročilo podjetja).
Opis

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Borze in oznake

BorzaOznakaValutaCenaVrsta
US USA StocksBIIB glavnaUSD218.43 -1.67%navadne delnice
LSE London Stock Exchange0R1B IOBUSD228.41 +0.00%navadne delnice
MX Mexican Stock ExchangeBIIB dodatnaMXN3 900.8 +0.00%navadne delnice

Cena v 3 mesecih

dan rasti dan padca ex-dividendni datum datum izplačilaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Dividende

Ni bilo najdenih izplačil dividend (preverjeno 10.10.2026). Podjetje verjetno ne izplačuje dividend.

Novice ta teden

Novic s spletnega mesta podjetja še ni.

oglas

Največji imetniki

ImetnikDeležDelniceDatum poročila
FMR, LLC12.33%18.22 mio.2026-06-30
Blackrock Inc.10.82%15.99 mio.2026-06-30
Primecap Management Comp…10.26%15.15 mio.2026-06-30
Vanguard Capital Managem…6.53%9.65 mio.2026-06-30
VANGUARD CHESTER FUNDS-V…5.66%8.36 mio.2026-06-30
State Street Corporation4.97%7.34 mio.2026-06-30
Vanguard Portfolio Manag…4.47%6.6 mio.2026-06-30
Fidelity Contrafund3.37%4.98 mio.2026-07-31
VANGUARD INDEX FUNDS-Van…3.17%4.69 mio.2026-06-30
Geode Capital Management…3.01%4.45 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%3.83 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.17%3.2 mio.2026-06-30
Wellington Management Gr…2.11%3.12 mio.2026-06-30
VANGUARD HORIZON FUNDS-V…1.78%2.62 mio.2026-06-30
NORGES BANK1.75%2.58 mio.2026-06-30
VANGUARD SPECIALIZED FUN…1.71%2.53 mio.2026-04-30
Morgan Stanley1.63%2.41 mio.2026-06-30
iShares Trust-iShares Co…1.35%1.99 mio.2026-07-31
Fidelity Concord Street…1.29%1.91 mio.2026-07-31
SPDR S&P 500 ETF TRUST-S…1.23%1.81 mio.2026-08-31
ALEXANDER SUSAN H (Offic…≈0.04%61 8892026-02-06
DORSA CAROLINE D (Direct…≈0.02%31 0022025-06-17
VIEHBACHER CHRISTOPHER (…≈0.02%29 9242026-02-06
ROWINSKY ERIC K. (Direct…≈0.02%25 8442026-06-09
MCDONNELL MICHAEL R (Chi…≈0.02%24 3412025-02-10
GREGORY GINGER (Officer)≈0.02%22 3582026-02-06
MURPHY NICOLE (Officer)≈0.01%19 6112026-02-12
SHERWIN STEPHEN A (Direc…≈0.01%15 1932026-06-09
KRAMER ROBIN C. (Chief F…≈0.01%11 4712026-02-06
MANTAS JESUS B (Director…≈0.01%11 2632026-06-09
Renaissance Technologies———